Valeant Pharmaceuticals International (VRX) · page 26 of 47
The slide uses a 'However' transition to pivot from a standard valuation to a more complex, asset-based argument.
Conference presentation · valuation_reveal · show_valuation_bridge · dense density
Slide locked Sign in to view
Slide schematic 4/4
callout 3/3 source-note 1/1
Components 4
primary primary primary source-note
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1